Peripheral and central blockade of interleukin-6 trans-signaling differentially affects sleep architecture  by Oyanedel, Carlos N. et al.
Brain, Behavior, and Immunity 50 (2015) 178–185Contents lists available at ScienceDirect
Brain, Behavior, and Immunity
journal homepage: www.elsevier .com/locate /ybrbiPeripheral and central blockade of interleukin-6 trans-signaling
differentially affects sleep architecturehttp://dx.doi.org/10.1016/j.bbi.2015.07.001
0889-1591/ 2015 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Institute of Medical Psychology and Behavioral
Neurobiology, University of Tübingen, FIN-Building, Otfried-Müller-Strasse 25,
72076 Tübingen, Germany.
E-mail address: jan.born@uni-tuebingen.de (J. Born).
1 These authors contributed equally to this work.Carlos N. Oyanedel a,b,1, Eduard Kelemen a,c,1, Jürgen Scheller d, Jan Born a,c,e,⇑, Stefan Rose-John f
a Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Germany
bGraduate School of Neural & Behavioural Sciences, International Max Planck Research School, Tübingen, Germany
cGerman Center for Diabetes Research (DZD), Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen (IDM),
Tübingen, Germany
d Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany
eCenter for Integrative Neuroscience, University of Tübingen, Germany
fDepartment of Biochemistry, University of Kiel, Germanya r t i c l e i n f o
Article history:
Received 11 May 2015
Received in revised form 24 June 2015
Accepted 1 July 2015







Theta rhythma b s t r a c t
The immune system is known to essentially contribute to the regulation of sleep. Whereas research in
this regard focused on the pro-inﬂammatory cytokines interleukin-1 and tumor necrosis factor, the role
of interleukin-6 (IL-6) in sleep regulation has been less intensely studied, probably due to the so far seem-
ingly ambiguous results. Yet, this picture might simply reﬂect that the effects of IL-6 are conveyed via two
different pathways (with possibly different actions), i.e., in addition to the ‘classical’ signaling pathway
via the membrane bound IL-6 receptor (IL-6R), IL-6 stimulates cells through the alternative
‘trans-signaling’ pathway via the soluble IL-6R. Here, we concentrated on the contributions of the
trans-signaling pathway to sleep regulation. To characterize this contribution, we compared the effect
of blocking IL-6 trans-signaling (by the soluble gp130Fc fusion protein) in the brain versus body periph-
ery. Thus, we compared sleep in transgenic mice expressing the soluble gp130Fc protein only in the brain
(GFAP mice) or in the body periphery (PEPCK mice), and in wild type mice (WT) during a 24-h period of
undisturbed conditions and during 18 h following a 6-h period of sleep deprivation. Compared with WT
mice, PEPCK mice displayed less sleep, particularly during the late light phase, and this was accompanied
by decreases in slow wave sleep (SWS) and rapid eye movement (REM) sleep. Following sleep deprivation
PEPCK mice primarily recovered REM sleep rather than SWS. GFAP mice showed a slight decrease in REM
sleep in combination with a profound and persistent increase in EEG theta activity. In conclusion, periph-
eral and central nervous IL-6 trans-signaling differentially inﬂuences brain activity. Peripheral IL-6
trans-signaling appears to more profoundly contribute to sleep regulation, mainly by supporting SWS.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The immune system profoundly inﬂuences the pattern of sleep,
not only in many pathological conditions but even under normal
physiological conditions (Krueger, 2008; Imeri and Opp, 2009;
Lange et al., 2010; Besedovsky et al., 2012). This inﬂuence is
thought to be conveyed via the release of cytokines from immune
cells in the body periphery or in the brain itself. Whereas studies
have so far focused on the role of the pro-inﬂammatory cytokinesinterleukin-1 and tumor necrosis factor, which appear to regulate
sleep via an action on slow wave sleep (SWS) promoting mecha-
nisms (Takahashi et al., 1999; Clinton et al., 2011; Jewett and
Krueger, 2012; Schmidt et al., 2015), possible contributions of
IL-6 signaling to sleep regulation received less attention, which
might be partly ascribed to the seemingly inconclusive pattern of
result from these studies. Thus, in humans, an association was
reported between impaired sleep and elevated IL-6 and cortisol
levels (Vgontzas et al., 2003; Burgos et al., 2006; Riemann et al.,
2009). IL-6 enhanced non-rapid eye movement (NonREM) sleep
in rats (Hogan et al., 2003), and enhanced slow wave activity dur-
ing SWS in humans (Benedict et al., 2009), suggesting IL-6 signal-
ing to favor SWS-related processes. However, IL-6 knock-out
mice spent more time in REM sleep than control mice (Morrow
and Opp, 2005a). Additionally, these mice showed a slower
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experiments no effects of IL-6 on sleep were observed in rabbits
(Opp et al., 1989), and antagonizing IL-6 activity by neutralizing
antibodies in rats also did not affect sleep (Hogan et al., 2003).
The heterogeneity of IL-6 effects on sleep observed in previous
studies could be at least partially due to the fact that IL-6 can act
on cells through two different signaling pathways, classical signal-
ing and trans-signaling. In classic signaling, IL-6 binds to a
membrane-bound receptor (mbIL-6R). Thereafter, the
IL-6/mbIL-6R complex interacts with the trans-membrane protein
gp130, inducing its dimerization and downstream signaling via the
JAK/STAT pathway (Heinrich et al., 2003; Rose-John, 2012). Only
cells, which express mbIL-6R are able to respond to IL-6 via classic
signaling. In trans-signaling, IL-6 binds to a soluble form of the
receptor (sIL-6R), present in the extracellular space. This complex
of IL-6/sIL-6R can stimulate gp130 expressing cells, including those
that lack membrane-bound IL-6R (Rose-John, 2012). Of note, the
latter cells are completely unresponsive to IL-6 alone (Rose-John,
2012). Whereas membrane-bound IL-6R is mostly expressed by
hepatocytes and some leukocytes, gp130 is expressed by virtually
all cells in the body including different types of glia cells (März
et al., 1999) and neurons (März et al., 1998). Accordingly, IL-6
trans-signaling has been demonstrated to be of particular impor-
tance in the central nervous system (CNS) (Campbell et al., 2014).
The present study aimed at dissecting the contributions of IL-6
trans-signaling in the body periphery and in the CNS on sleep reg-
ulation. In this vein, it complements and extends previous experi-
ments (May et al., 2009), in which we stimulated IL-6
trans-signaling by an introcerebroventricular infusion of
Hyper-IL-6 (a fusion protein of human IL-6 and human soluble
IL-6 receptor, Fischer et al., 1997) in rats. In that study, stimulation
of the IL-6 trans-signaling pathway increased REM sleep and
decreased power of the EEG theta activity during REM sleep. In
the present study, we selectively blocked IL-6 trans-signaling in
the CNS or in the body periphery. To this end two different types
of transgenic mice were used, which expressed a soluble and
dimerized form of gp130 (sgp130Fc) – a fusion protein that selec-
tively inhibits IL-6 trans-signaling, and leaves classic signaling via
the membrane-bound IL-6R intact (Jostock et al., 2001; Rabe et al.,
2008; Braun et al., 2013; Campbell et al., 2014). In one transgenic
line (PEPCKmice) IL-6 trans-signaling was blocked in the periphery
whereas in the other line (GFAP mice) it was blocked in the CNS.
The two groups of mice were compared to age-matched C57Bl/6J
wild type (WT) mice. We compared the sleep architecture and
EEG between the three groups during 24 h in undisturbed condi-
tions, and during 18 h of recovery from a 6-h period of sleep depri-
vation. We hypothesized that central blockade of IL-6
trans-signaling induced effects opposite to those seen after central
nervous administration of Hyper-IL-6 in a previous study (May
et al., 2009), i.e., a decreasing rather than increasing effect on
REM sleep, whereas peripheral blocking of IL-6 trans-signaling
was suspected to suppress promoting effects on sleep and SWS,
which were associated with IL-6 activity in previous studies.2. Material and methods
2.1. Animals
Mice of three different genotypes were used. The ﬁrst line of
transgenic mice expressed sgp130Fc as a transgene from a liver
promoter PEPCK (PEPCK group, Rabe et al., 2008); therefore,
sgp130Fc was present in the blood and peripheral body ﬂuids.
The second line of transgenic mice expressed sgp130Fc as a trans-
gene from the astrocyte speciﬁc GFAP promoter (GFAP group,
Campbell et al., 2014), producing high levels of the protein in theCNS. Eleven PEPCK-sgp130Fc mice with C57BL/6J background,
eight GFAP-sgp130Fc mice with C57BL/6J background, and eleven
wild type C57BL/6J mice (aged between 8 and 12 weeks) were
used. The transgenic mice were generated at one of the coauthors
lab (S.R.-J.), and the genotypes were veriﬁed by PCR analysis of tail
and hear DNA. The transgenic mice do not exhibit any apparent
behavioral alteration. Animals were housed and experiments were
performed at controlled temperature (20 ± 2 C) and humidity
(55 ± 10%), and a controlled 12 h/12 h light/dark cycle with light
onset at 6 a.m. Water and food were available ad libitum. All exper-
imental procedures were performed in accordance with the
European animal protection laws and policies (Directive 86/609,
1986, European Community) and were approved by the
Baden-Württemberg state authority (MPV 1/12).
2.2. Surgery
The animals were anesthetized with intraperitoneal injection of
fentanyl (0.05 mg/kg of body weight), midazolam (5.00 mg/kg),
and medetomidin (0.50 mg/kg). They were placed into a stereo-
taxic frame and were supplemented with isoﬂurane anesthesia
(0.5%) as necessary. The scalp was removed and 4 holes were
drilled into the skull. Four EEG screw electrodes were implanted:
one frontal electrode (AP: +1.5 mm, L: +1.0 mm, relative to
Bregma), two parietal (AP: 2.0 mm, L: ±2.5 mm), and one occipi-
tal reference electrode (AP: 10.0 mm, L: 0 mm). Two stainless
steel wire electrodes were implanted bilaterally in the neck mus-
cles for EMG recordings. The electrodes were ﬁxed to the skull with
cold polymerizing dental resin and the wound was sutured. At the
end of the surgery, an anesthesia antidote (naloxone 1.2 mg/kg,
ﬂumazenil 0.5 mg/kg, and atipamezole 2.5 mg/kg) was applied
subcutaneously. The animals were given analgesics (carprofen
0.05 mg/kg) for 3 days following the surgery. At least seven days
were allowed for recovery.
2.3. Experimental protocol and EEG/EMG recordings
The recordings took place in a quadratic recording box
(30  30 cm, 40 cm high) made of dark gray PVC. Mice were habit-
uated to the recording box for two days. After habituation, the EEG
and EMGwere recorded continuously for 48 h. During the ﬁrst 24 h
the mice were left undisturbed. The second day started with a 6-h
period of sleep deprivation, followed by an 18-h recovery period.
Sleep deprivation was achieved by gentle handling; if the animal
displayed a sleeping posture and the EEG conﬁrmed signs of sleep
the mouse was aroused by tapping on the box, gently shaking the
box or, if necessary, disturbing the nest. Note, because gentle han-
dling starts with conﬁrmation of EEG signs of sleep and may not
immediately arouse the animal, the procedure does not completely
abandon sleep. During recordings, the electrodes were connected
through a swiveling commutator to an ampliﬁer (Model 15A54,
Grass Technologies, USA). EEG and EMG signals were ampliﬁed, ﬁl-
tered (EEG: 0.01–300 Hz; EMG: 30–300 Hz), and sampled at a rate
of 1017 Hz.
2.4. Assessment of sleep-wake architecture
Sleep stages, i.e., slow wave sleep (SWS), pre-rapid eye move-
ment (pre-REM) sleep, and rapid eye movement (REM) sleep, and
wakefulness were scored off-line by visual inspection using 10-s
epochs according to standard criteria (Neckelmann et al., 1994).
Pre-REM is scored speciﬁcally in rodents and normally occurs at
the transition into REM sleep. It is mainly characterized by a pro-
gressive decrease in EEG slow wave activity and EMG activity,
and a concurrent increase in EEG theta activity. For sleep scoring,
the Sleep-Sign for Animal software (Kissei Comtec, Japan) was
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during succeeding two hour intervals and (ii) the percentage of
sleep time spent in a speciﬁc sleep stage during succeeding 2-h
intervals was determined. Additionally, duration and number of
sleep episodes, SWS, pre-REM and REM sleep episodes were calcu-
lated for succeeding 2-h intervals.
Additionally, the EEG pattern during each sleep/wake state was
characterized using Fast Fourier Transformation. Epochs contain-
ing EEG artifacts were excluded from spectral analyses. For SWS
average power was computed for the slow-wave activity (SWA,
0.5–4.0 Hz), slow oscillation (0.5–2.0 Hz) and delta (2.0–4.0 Hz)
frequency bands. For REM sleep and pre-REM sleep average power
for the theta band (4.0–10.0 Hz) was calculated.
Sleep spindles were detected using an algorithm described in
detail by Eschenko et al. (2006). Brieﬂy, EEG signals were ﬁltered
between 12 and 15 Hz, the root mean square (rms) of the ﬁltered
signals was calculated, and the episodes where the rms signal
was 1.5 SD above the mean for periods longer than 0.5 s were
scored as spindle events.2.5. Statistical analyses
Differences in sleep architecture, as well as in EEG power spec-
tra among genotypes were analyzed using Analysis of Variance
(ANOVA) including the group factor ‘genotype’ (the three mice
strains of interest) and, when appropriate, the repeated-measures
factor ‘time’ (representing the succeeding 2-h intervals). The
Greenhouse–Geisser correction of degrees of freedom was applied
where appropriate. We used two-sampled Student’s t-tests to
specify signiﬁcant ANOVA main and interaction effects. Note, post
hoc comparisons were only performed when ANOVA revealed sig-
niﬁcance for a test of interest. Because the ANOVA was considered
the primary statistical tests, we did not introduce any correction
for multiple comparison (e.g., Bonferroni) for the post-tests. A
p < 0.05 (two-tailed) was considered signiﬁcant. For statistical
analysis, the SPSS 21.0 software (IBM, Armonk, USA) was used.3. Results
3.1. 24-h sleep-wake architecture
Fig. 1 summarizes the time spent awake, in SWS, pre-REM and
REM sleep for succeeding 2-h intervals across the 24-h cycle, sep-
arately for the three mouse strains. As expected in a nocturnal spe-
cies, mice were mostly awake during the dark period of the day
and much less awake during the light period. PEPCK mice, with
peripheral blockade of IL-6 trans-signaling, showed a distinct
increase in the time spent awake, which focused on the second half
of the light period (F(22,297) = 2.07, p = 0.004, for genotype  time
interaction, see Fig. 1A for post hoc pairwise comparisons between
GFAP and WT mice). Consistent with this increased time spent
awake, PEPCK mice spent less time in all sleep stages, especially
towards the end of the light period. Thus PEPCK mice showed less
SWS (F(16.589,223.954) = 1.78, p = 0.033, for genotype  time),
less time in pre-REM sleep (F(13.369,180.479) = 3.13, p < 0.001,
for genotype  time, (F(2,27) = 6.02, p = 0.007, for genotype main
effect) and less time in REM sleep (F(22,297) = 2.86, p < 0.001
(F(11,297) = 39.28, p < 0.001, for genotype  time; (F(2,27) = 7.15,
p = 0.003, for genotype main effect) than the WT control mice
(see Fig. 1B–D, for respective post hoc pairwise comparisons).
Sleep in GFAP mice, with CNS blockade of IL-6 trans-signaling,
did not differ from sleep in WT mice except for a slight decrease
in time in REM sleep (F(1,17) = 7.20, p = 0.016).
The decreased sleep time during the late light period in PEPCK
mice was associated with a decreased number of episodes inSWS, pre-REM sleep and REM sleep (F(10,135) = 2.62, p = 0.006,
F(10,135) = 3.65, p < 0.001, and F(10,135) = 1.99, p = 0.039, respec-
tively, for genotype  time). The duration of episodes were not
changed in the PEPCK mice (all p‘s > 0.3).
Fig. 2 shows the percentages (of sleep time) spent in the differ-
ent sleep stages during the 24-h cycle for the three strains). The
proportion of SWS within sleep period was increased in PEPCK
mice compared to the other two mice strains (F(2,26) = 5.52,
p = 0.010), with this effect more pronounced during the late light
phase (F(12.995,168.931) = 1.56, p = 0.1, for genotype  time, see
Fig. 2A, for respective post hoc pairwise comparisons. By contrast
proportions of pre-REM sleep and REM sleep were decreased in
PEPCK mice (F(2,26) = 3.96, p = 0.031 and F(2,26) = 4.80,
p = 0.017, for respective main effects of genotype. Post-hoc pair-
wise comparisons (Fig. 2B and C) revealed this effect to be partic-
ularly robust during the late light period, although respective
genotype  time ANOVA interaction effects failed to reach signiﬁ-
cance (p’s > 0.15).
3.2. EEG power spectra during wake and speciﬁc sleep stages, spindles
Fig. 3 shows average power spectra during wake, SWS, pre-REM
sleep and REM sleep for the three genotypes. All genotypes showed
the typical increase in theta power (4.0–10.0 Hz) during wakeful-
ness, pre-REM sleep, and REM sleep (in comparison with SWS),
and the typical increase in slow wave activity (SWA, 0.5–4.0 Hz)
during SWS and pre-REM sleep. Notably, GFAP mice (with blocked
CNS IL-6 trans-signaling) displayed distinctly higher theta power
basically throughout the whole recording period. This increase
was very prominent during the stages characterized by high theta
activity, i.e., wakefulness, pre-REM sleep and REM sleep compared
to the other two strains (F(2,26) = 4.21, p = 0.026, F(2,26) = 4.76,
p = 0.017, and F(2,26) = 4.30, p = 0.024, for respective main effect
of genotype, see Fig. 3 for respective pairwise comparisons), but
also reached signiﬁcance in an additional analysis performed on
SWS (F(2,26) = 4.22, p = 0.026). No signiﬁcant differences between
strains were found for SWA (0.5–4.0 Hz) or the slow oscillation
(0.5–2.0 Hz) and delta (2.0–4.0 Hz) sub-frequency bands (all
p‘s > 0.2).
Analysis of spindles during SWS revealed a slight increase in
spindle density (number of spindles per minute SWS) from the
beginning to the end of the light period, followed by a drop right
after the lights were turned off. However, these dynamics were
not signiﬁcantly altered in the two transgenic strains (p‘s > 0.3).
Also average spindle density was comparable for the three strains
(WT: 1.87 ± 0.07/min, PEPCK: 1.99 ± 0.13/min, GFAP: 1.92 ± 0.09/
min, p > 0.6).
3.3. Sleep deprivation
Sleep deprivation by gentle handling decreased time asleep
during the 6-h interval by 74.95 ± 1.08%, compared with the corre-
sponding time interval in undisturbed conditions, 24 h earlier.
Recovery sleep as well as differences in recovery sleep between
the strains concentrated on the 6-h interval following sleep depri-
vation (Fig. 4). WT mice recovered primarily SWS. Accordingly,
these mice showed a signiﬁcant increase in SWS (p = 0.040) accom-
panied by an increase in slow wave activity during SWS (p = 0.029)
in the 6-h interval following sleep deprivation, compared with the
corresponding 6-h interval in undisturbed conditions, 24 h before,
whereas time in REM sleep was unchanged and time in pre-REM
even decreased (p = 0.004) during this interval. The rebound in
SWS was likewise seen in GFAP mice (p = 0.050) but, not in
PEPCK mice (p = 0.333), and both mutants did not exhibit any
rebound in slow wave activity during SWS (p > 0.271). The
respective genotype  time interactions failed to reach signiﬁcance
Fig. 1. Sleep during the 24-h cycle. Time (in min) spent (A) awake, (B) in SWS; (C) pre-REM sleep; and (D) REM sleep for succeeding 2-h intervals during light (empty bar on x
axis) and dark period (black bar). Recordings started at 6:00 am. Wild-type (WT) mice – black lines, PEPCK mice – gray lines, GFAP mice – dashed line. Means ± SEM are
shown. Signiﬁcant differences (obtained from post hoc Student’s t-tests, uncorrected for multiple comparisons) are indicated between WT and PEPCK mice by ⁄, between WT
and GFAP mice by , between PEPCK and GFAP mice by # (single, double, triple symbols – p < 0.05, p < 0.01, p < 0.001, respectively).
Fig. 2. Percentages (of time in sleep) of SWS (A), pre-REM sleep (B), and REM sleep (C) for succeeding 2-h intervals during the 24-h cycle in WT mice (black lines), PEPCK mice
(gray lines), and GFAP mice (dashed lines). Signiﬁcant (obtained from post hoc Student’s t-tests, uncorrected for multiple comparisons) differences are marked as in Fig. 1.
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Fig. 3. EEG power spectra. Mean (±SEM) power spectra are shown separately for the four sleep/wake stages: (A) wake, (B) SWS, (C) pre-REM sleep, and (D) REM sleep, and
separately for the three mouse strains (WT mice – black lines, PEPCK mice – gray lines, GFAP mice – dashed lines), across the whole 24-h cycle. Inserts show comparison of
average power in selected frequency bands: theta power (4.0–10.0 Hz) during wake, pre-REM sleep, and REM sleep; slow wave activity (SWA; 0.5–4.0 Hz) during SWS.
Signiﬁcant differences (obtained from post hoc Student’s t-tests, uncorrected for multiple comparisons) are indicated (*p 6 0.05).
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unlike WT mice, PEPCK mice showed a signiﬁcant rebound of
REM sleep during the 6-h recovery period (p = 0.009;
F(1,20) = 4.06, p = 0.058 for genotype  time). Also, PEPCK mice,
unlike WT mice, did not display any decrease in time in pre-REM
during the recovery period (p = 0.461, F(2,27) = 4.90, p = 0.015,
for genotype  time). Comparing the average time spent in the dif-
ferent sleep stages during the 6-h recovery period in particular
conﬁrmed the diverging sleep pattern in the PEPCK mice, which
spent more time awake and less time in SWS and pre-REM sleep
during this period (F(2,27) = 7.15, p = 0.003, (F(2,27) = 7.23,
p = 0.003 and F(2,27) = 6.74, p = 0.004, respectively, for main effect
of genotype, Fig. 4).
4. Discussion
We characterized the effects of peripheral and CNS blockade of
IL-6 trans-signaling on sleep using two different transgenic mice
strains, which express the selective IL-6 trans-signaling blocker
sgp130Fc (Jostock et al., 2001) from the liver speciﬁc PEPCK and
the astrocyte speciﬁc GFAP promoter. Our results show that block-
ade of IL-6 trans-signaling in the periphery and in the brain has
distinct effects. Blocking IL-6 trans-signaling in the periphery (in
PEPCK mice) suppressed sleep and thus increased the time animals
spent awake, with this effect focusing on the second late half of the
inactive (light) period. Concurrently, time in SWS, REM sleep and
pre-REM sleep was diminished. Blocking IL-6 trans-signaling in
the brain (in GFAP mice) slightly decreased REM sleep, incombination with a profound and persistent increase in EEG theta
activity (4.0–10.0 Hz). The increase in theta activity was observed
during virtually all wake and sleep states, and was most clearly
seen in the states characterized by high theta activity, i.e., wakeful-
ness, pre-REM sleep and REM sleep. Our data extend previous data
in demonstrating an involvement of IL-6 trans-signaling in sleep
regulation. We identify IL-6 trans-signaling in the periphery as a
factor that contributes to the maintenance of sleep, probably via
an activating inﬂuence on SWS generating mechanisms. By con-
trast, IL-6 trans-signaling in the CNS seems to mainly affect
theta-generating networks, with this effect being independent of
the brain state.
The mice models used in the present study to selectively block
IL-6 trans-signaling in the CNS and periphery have been estab-
lished in several previous studies (Rabe et al., 2008; Braun
et al., 2013; Campbell et al., 2014). Measurements of soluble
sgp130Fc levels in peripheral tissue (Rabe et al., 2008) and brain,
conﬁrmed highly increased peripheral sgp130Fc levels of 20–
30 lg/ml in the PEPCK mice whereas they were below the detec-
tion threshold in brain tissue in these mice. Conversely, GFAP
mice exhibited highly increased central sgp130Fc levels of 250–
350 ng/ml in the perfused brain homogenates and no elevated
sgp130Fc levels in the periphery. Moreover, the sgp130Fc protein
was clearly detectable by Western blotting in the supernatant of
primary astrocyte cultures from GFAP mice but not from WT mice
(Campbell et al., 2014). It has been also shown that sgp130Fc
does not cross the blood brain barrier under unchallenged condi-
tions (Braun et al., 2013).
Fig. 4. Recovery sleep after sleep deprivation. Time (in min) spent (A) awake, (B) in SWS, (C) pre-REM sleep and (D) REM sleep during an 18-h interval following a 6-h interval
of sleep deprivation (gray shaded area) during the early light period (empty bar on x axis). Wild-type (WT) mice – black lines, PEPCK mice – gray lines, GFAP mice – dashed
lines. Means ± SEM are shown. Inserts show average time spent in the different stages in the 6-h interval immediately following sleep deprivation. Signiﬁcant differences
(obtained from post hoc Student’s t-tests, uncorrected for multiple comparisons) are indicated: *p < 0.05, **p < 0.01, ***p < 0.001. Arrows above the bar indicate signiﬁcant
decrease (;) or increase (") with reference to the respective 6-h period in undisturbed sleep conditions, i.e., 24 h before (single, double symbols – p < 0.05, p < 0.01
respectively).
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trans-signaling (in the PEPCK mice) was the decrease in sleep time
towards the late light period, with this decrease being accompa-
nied by a reduction of number of episodes and time spent in each
of the 3 sleep stages. As the percentage of SWS relative to the time
spent in sleep, was enhanced during this period in the PEPCK mice
it might be argued that the SWS process per se is preserved in
these mice. However, probing sleep generating mechanisms by
total sleep deprivation revealed clear signs of reduced SWS
propensity in PEPCK mice. PEPCK mice not only exhibited reduced
average time in SWS during the recovery period. They also failed toshow a rebound in SWS or slow wave activity during this period
when compared to their SWS levels during corresponding period
of an undisturbed 24-h cycle. Different from WT mice, which pri-
marily recovered SWS, PEPCK mice primarily recovered REM sleep
during the 6-h period following sleep deprivation. The primary
recovery of REM sleep is noteworthy, given that the sequential
structure of sleep, with REM sleep always following SWS, is intact
in PEPCK mice. Indeed, it speaks for an effect of peripheral IL-6
trans-signaling on mechanisms inducing sleep that in such condi-
tions would promote, in the ﬁrst place, SWS. Yet, the possibility
cannot be entirely excluded that peripheral IL-6 trans-signaling
184 C.N. Oyanedel et al. / Brain, Behavior, and Immunity 50 (2015) 178–185additionally directly suppresses REM sleep. This view would not
only be consistent with the profound recovery of REM sleep
observed in the PEPCK mice after total sleep deprivation but also
with ﬁndings in IL-6 knock-out mice, which showed generally
enhanced REM sleep (Morrow and Opp, 2005a).
Contrasting with the effects of peripheral blockade, CNS block-
ade of IL-6 trans-signaling in the GFAP mice did not alter sleep
architecture, except for a slight decrease in REM sleep. The much
more prominent change in GFAP mice was the persistent increase
in theta activity. These changes strikingly complement the oppo-
site effects observed after stimulating central IL-6 trans-signaling
by intracerebroventricular administration of the designer cytokine
Hyper-IL-6 (May et al., 2009). Interestingly, stimulation of classic
signaling by the injection of IL-6 did not show this effect.
Hyper-IL-6 reduced EEG theta activity, and this effect was accom-
panied by increased time in REM sleep. In combination, these
results reveal theta-generating networks as a primary target of
central nervous IL-6 trans-signaling. The theta increase in the
EEG most likely reﬂects theta rhythm in the hippocampus as the
major source of this rhythm in the rodent brain (Vanderwolf and
Leung, 1983; Buzsáki, 2002). Considering the strong involvement
of this rhythm in processing of spatial and episodic memory infor-
mation (Whishaw and Vanderwolf, 1973; Buzsáki, 2005), future
studies are indicated to examine the functionality of the increase
in theta activity characterizing the GFAP mice.
While our results indicate that sleep-regulatory actions of IL-6
via the trans-signaling pathway mainly originate from the body
periphery rather than CNS, we can only speculate about the medi-
ating mechanisms and cells that convey inﬂuences of peripheral
IL-6 trans-signaling to central nervous sleep-generating networks.
The gp130 protein is expressed by virtually all cells in the body.
Consequently, quite different pathways might be involved in this
mediation process, including direct actions on afferent neurons of
the vagus nerve (Goehler et al., 2000; Garcia-Oscos et al., 2015),
on endocrine signals that cross the blood brain barrier (e.g.,
Späth-Schwalbe et al., 1996), or on cells of the blood–brain barrier
regulating its permeability for other sleep-regulating signals
(Brunello et al., 2000). Whatever the mediating mechanisms are,
it is to note that the present alterations in sleep observed in
PEPCK mice after peripheral blockade of IL-6 trans-signaling are
well in line with major ﬁndings from previous studies examining
inﬂuences on sleep following experimental manipulation of the
IL-6 signal itself, rather than manipulating receptor pathways.
Thus, IL-6 knock-out mice showed a delayed recovery of sleep after
sleep deprivation (Morrow and Opp, 2005a), and when treated
with lipopolysaccharide displayed diminished increases in SWS
(Morrow and Opp, 2005b). In healthy men, administration of IL-6
enhanced SWS (Späth-Schwalbe et al. 1998; Benedict et al.,
2009), and in pathological conditions, increased blood IL-6 concen-
trations were found to be associated with signs of sickness behav-
ior including sleepiness (Vgontzas et al., 2005). Collectively these
ﬁndings converge to the view that peripheral IL-6 via
trans-signaling supports sleep by promoting sleep and SWS. The
view is further corroborated by ﬁndings indicating that sleep is a
condition substantially increasing circulating soluble IL-6 recep-
tors and is, thus, associated with an upregulated trans-signaling
in the body periphery (Dimitrov et al. 2006).
Our ﬁndings indicating stronger sleep-regulatory inﬂuences of
peripheral than central IL-6 trans-signaling might surprise. Why
should a peripheral cytokine signal be more potent than a central
in promoting sleep? Possibly, this relates to the function of IL-6,
signaling to the brain an increased need for sleep in conditions of
acute infection, which mainly arise in the body periphery.
Indeed, sleep-regulatory effects of IL-6 were also revealed to essen-
tially depend on the presence or absence of an immune challenge
(Morrow and Opp, 2005b; Campbell et al., 2014). Hence, the fullcharacterization of the role of IL-6 in sleep regulation requires
not only to directly compare effects of blocking trans-signaling
and classical pathways, but should also comprise examinations of
the two pathways in immunologically challenged and unchal-
lenged conditions.
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